Variational AI

Variational AI - Enki Platform is an AI-powered drug discovery platform that generates novel, drug-like small molecules tailored to defined targets and properties. It leverages an ensemble of generative algorithms trained on decades of experimental data to produce lead structures rapidly, with the ability to target 570+ biology targets across multiple classes (GPCRs, kinases, hydrolases, proteases, NHRs, integrins, and more). The platform emphasizes speed, selectivity, and cost efficiency in early-stage drug discovery, enabling researchers to define desired target profiles and receive optimized chemistry suggestions in weeks rather than months.

How to Use Variational AI Enki

1. Define your Target and Properties. Use the TPP (Target Product Profile) to specify on-target(s), off-targets, and other essential properties.
2. Select Targets. Choose among 570+ targets spanning diverse classes.
3. Run Enki Generative Engine. The platform generates novel, synthesizable lead structures aligned with your specifications.
4. Review and Iterate. Evaluate suggested molecules for drug-likeness, novelty, and synthetic feasibility; iterate by adjusting the TPP as needed.

Why Enki Exists

• Enki is described as the first commercially accessible foundation model for small molecules, designed to accelerate lead generation and reduce unit economics challenges in drug discovery.
• It is built to work with biopharmaceutical partners, delivering actionable chemical ideas in weeks.
• The system is trained on extensive historical and experimental data to support reliable candidate generation.

Target Coverage

• 570+ targets across multiple classes, including GPCRs, kinases, hydrolases, proteases, NHRs, integrins, and more.

Our Team and Vision

• A multidisciplinary team of AI/machine learning researchers and medicinal chemistry experts focused on applying state-of-the-art generative AI to drug discovery, in collaboration with industry partners to bring new therapeutics to market.

News and Activities

• Funding announcements and partnerships highlighting the platform’s adoption by biopharma companies for accelerated drug discovery programs.

Core Features

• Generative AI platform for small molecule lead discovery
• Define Target Product Profile (on-target/off-target properties) in minutes
• Access to 570+ biological targets across multiple classes
• Rapid lead generation designed to shorten discovery timelines from months to weeks
• Synthesizability and drug-likeness considerations embedded in generation
• Foundational model approach for scalable, repeatable chemistry ideas
• Collaboration-ready with biopharmaceutical partners
• Industry news and ongoing product updates and funding rounds